Working… Menu
Trial record 1 of 1 for:    NCT03220958
Previous Study | Return to List | Next Study

Metoclopramide for Post Traumatic Headache

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03220958
Recruitment Status : Completed
First Posted : July 18, 2017
Last Update Posted : June 24, 2021
Information provided by (Responsible Party):
Montefiore Medical Center

Brief Summary:
Nearly 1.5 million patients present to US emergency departments annually following head trauma. Headache is a frequent symptom of victims of head trauma. The purpose of this study is to see if an intravenous medication called metoclopramide can improve the symptoms of patients with acute post-traumatic headache.

Condition or disease Intervention/treatment Phase
Post-Traumatic Headache Drug: Metoclopramide Drug: Diphenhydramine Drug: Normal saline Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Placebo Controlled Trial of IV Metoclopramide for Acute Post-traumatic Headache
Actual Study Start Date : August 1, 2017
Actual Primary Completion Date : April 1, 2020
Actual Study Completion Date : April 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Headache

Arm Intervention/treatment
Experimental: Metoclopramide
Metoclopramide 20mg + diphenhydramine 25mg + 100cc normal saline, administered as an intravenous drip
Drug: Metoclopramide
Metoclopramide 20mg

Drug: Diphenhydramine
Diphenhydramine 25mg

Drug: Normal saline
100ml normal saline

Placebo Comparator: Placebo
Normal saline, administered as an intravenous drip
Drug: Normal saline
100ml normal saline

Primary Outcome Measures :
  1. Numerical rating scale for pain [ Time Frame: 1 hour after medication administration ]
    Improvement in this 0 to 10 verbal rating scale

Secondary Outcome Measures :
  1. Sustained headache relief [ Time Frame: 48 hours after medication administration ]
    Achieving a headache intensity of mild or none in the ED without use of rescue medication and maintaining a level of mild or none.

  2. Headache days [ Time Frame: 7 days after ED visit ]
    Number of days with any headache

  3. The Sport Concussion Assessment Tool (SCAT) Post Concussion Symptom Scale (PCSS). [ Time Frame: 48 hours, 7 days, and 1 month ]
    On this validated instrument, patients rate 25 symptoms on a 0 to 6 scale.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Included patients will be adults who meet International Classification of Headache Disorders criteria for acute post-traumatic headache. These are as follows:

  • Traumatic injury to the head has occurred
  • Headache has developed within 7 days of injury to the head
  • Headache is not better accounted for by another diagnosis (eg, previous history of migraine or tension-type headache)

The headache must be rated as moderate or severe in intensity at the time of initial evaluation.

Exclusion Criteria:

Patients will be excluded if more than ten days have elapsed since the head trauma, if the headache has already been treated with an anti-dopaminergic medication, or for medication contra-indications including pheochromocytoma, seizure disorder, Parkinson's disease, use of MAO inhibitors, and use of anti-rejection transplant medications.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03220958

Layout table for location information
United States, New York
Montefiore Medical Center
Bronx, New York, United States, 10467
Sponsors and Collaborators
Montefiore Medical Center
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Montefiore Medical Center Identifier: NCT03220958    
Other Study ID Numbers: 2017-7898
First Posted: July 18, 2017    Key Record Dates
Last Update Posted: June 24, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Post-Traumatic Headache
Neurologic Manifestations
Headache Disorders, Secondary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Sleep Aids, Pharmaceutical
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anesthetics, Local
Sensory System Agents
Peripheral Nervous System Agents
Autonomic Agents
Gastrointestinal Agents
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Allergic Agents